OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review
Bianca Raffaelli, Roberto De Icco, Michele Corrado, et al.
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 15
Bianca Raffaelli, Roberto De Icco, Michele Corrado, et al.
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 15
Showing 15 citing articles:
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 44
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 44
From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment
Masaru Tanaka, Ágnes Szabó, Tamás Körtési, et al.
Cells (2023) Vol. 12, Iss. 22, pp. 2649-2649
Open Access | Times Cited: 40
Masaru Tanaka, Ágnes Szabó, Tamás Körtési, et al.
Cells (2023) Vol. 12, Iss. 22, pp. 2649-2649
Open Access | Times Cited: 40
One-Year Compliance After Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy for Migraine Patients in a Real-World Setting: A Multicenter Cross-Sectional Study
Mi‐Kyoung Kang, Jong‐Hee Sohn, Myoung-Jin Cha, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 734-734
Open Access
Mi‐Kyoung Kang, Jong‐Hee Sohn, Myoung-Jin Cha, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 734-734
Open Access
Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study
Alessia Bellotti, Caterina Podella, Paola Sarchielli
Cephalalgia Reports (2025) Vol. 8
Open Access
Alessia Bellotti, Caterina Podella, Paola Sarchielli
Cephalalgia Reports (2025) Vol. 8
Open Access
Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine
Mengyi Li, Siyong Huang, Jiabao Li, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 1231-1247
Open Access
Mengyi Li, Siyong Huang, Jiabao Li, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 1231-1247
Open Access
Fremanezumab for refractory migraine in patients with hereditary transthyretin amyloidosis: A case series
Joana Fernandes, Sofia Ferreira, Cristina Alves, et al.
Cephalalgia Reports (2025) Vol. 8
Open Access
Joana Fernandes, Sofia Ferreira, Cristina Alves, et al.
Cephalalgia Reports (2025) Vol. 8
Open Access
Früherer Behandlungsbeginn mit Antikörpern gegen CGRP sinnvoll
Hans‐Christoph Diener
InFo Neurologie + Psychiatrie (2025) Vol. 27, Iss. 3, pp. 18-19
Closed Access
Hans‐Christoph Diener
InFo Neurologie + Psychiatrie (2025) Vol. 27, Iss. 3, pp. 18-19
Closed Access
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine
Britt W. H. van der Arend, Nancy van Veelen, J. Ruijter, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 2
Britt W. H. van der Arend, Nancy van Veelen, J. Ruijter, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 2
Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment
Marina Romozzi, Andrea Burgalassi, Catello Vollono, et al.
Confinia Cephalalgica (2024) Vol. 34, Iss. 1
Open Access | Times Cited: 2
Marina Romozzi, Andrea Burgalassi, Catello Vollono, et al.
Confinia Cephalalgica (2024) Vol. 34, Iss. 1
Open Access | Times Cited: 2
New migraine drugs
Francesca Puledda, Cristina Tassorelli, Hans‐Christoph Diener
Cephalalgia (2023) Vol. 43, Iss. 3
Open Access | Times Cited: 4
Francesca Puledda, Cristina Tassorelli, Hans‐Christoph Diener
Cephalalgia (2023) Vol. 43, Iss. 3
Open Access | Times Cited: 4
(CGRP) Monocloncal antibodies
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Neue Migränetherapeutika im Fokus
Hans‐Christoph Diener
InFo Neurologie + Psychiatrie (2023) Vol. 25, Iss. 7-8, pp. 22-23
Closed Access
Hans‐Christoph Diener
InFo Neurologie + Psychiatrie (2023) Vol. 25, Iss. 7-8, pp. 22-23
Closed Access
Neues bei Kopfschmerzen 2022–2023
Hans‐Christoph Diener, Dagny Holle, Charly Gaul
Neurologie up2date (2023) Vol. 06, Iss. 04, pp. 345-365
Closed Access
Hans‐Christoph Diener, Dagny Holle, Charly Gaul
Neurologie up2date (2023) Vol. 06, Iss. 04, pp. 345-365
Closed Access
